Brainstorm Cell Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.41; its P/E ratio is -1.28; Brainstorm Cell Therapeutics is scheduled to report earnings on May 10, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22
Income Statement	-
Total Revenue	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -5.45M	$ -5.15M	$ -4.92M	$ -6.84M	$ -7.59M
EBITDA	$ -5.38M	$ -5.08M	$ -4.84M	$ -6.77M	$ -7.52M
Net Income Common Stockholders	$ -5.57M	$ -5.06M	$ -5.02M	$ -6.86M	$ -7.04M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 748.00K	$ 2.23M	$ 2.98M	$ 7.39M	$ 12.24M
Total Assets	$ 5.75M	$ 7.87M	$ 8.45M	$ 13.25M	$ 18.96M
Total Debt	$ 3.29M	$ 3.68M	$ 4.09M	$ 4.38M	$ 4.74M
Net Debt	$ 2.54M	$ 1.45M	$ 1.11M	$ -3.02M	$ -7.50M
Total Liabilities	$ 9.63M	$ 12.71M	$ 11.47M	$ 11.87M	$ 11.11M
Stockholders Equity	$ -3.44M	$ -4.84M	$ -3.02M	$ 1.39M	$ 7.85M
Cash Flow	-
Free Cash Flow	$ -6.78M	$ -3.99M	$ -4.65M	$ -4.85M	$ -6.15M
Operating Cash Flow	$ -6.78M	$ -3.99M	$ -4.65M	$ -4.85M	$ -6.13M
Investing Cash Flow	$ 4.00K	$ 2.00M	$ 1.04M	$ -11.00K	$ -12.00K
Financing Cash Flow	$ 5.30M	$ 3.23M	$ 238.00K	$ 0.00	$ 0.00

Currency in USD

Brainstorm Cell Therapeutics Earnings and Revenue History

Income Statement >

Brainstorm Cell Therapeutics Debt to Assets

Balance Sheet >

Brainstorm Cell Therapeutics Cash Flow

Cash Flow >

Brainstorm Cell Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing